|
End-of-day quote
Shanghai S.E.
2026-09-21
|
5-day change | 1st Jan Change | ||
| 71.40 CNY | +3.61% |
|
+3.18% | +4.89% |
| 09-09 | Gan&Lee Pharmaceuticals Co., Ltd. Doses First Participant In First-In-Human Phase 1 Study Of GZC8072 Tablets | CI |
| 09-08 | Gan & Lee Pharmaceuticals Doses First Subject in Weight Loss Drug Trial | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- 603087 Stock
- Consensus Gan & Lee Pharmaceuticals.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
